Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $470.4M | $466.6M | $498.2M | $495.1M | $530.0M | $176.7M | $296.0M | $405.9M |
| Cost of revenue | $292.0M | $298.7M | $330.8M | $338.3M | $360.6M | $185.5M | $219.3M | $272.2M |
| Gross profit | $178.4M | $167.9M | $167.4M | $156.8M | $169.3M | −$8.8M | $76.6M | $133.7M |
| Gross margin | 37.9% | 36.0% | 33.6% | 31.7% | 32.0% | -5.0% | 25.9% | 32.9% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $82.4M | $65.5M | $49.6M | $52.7M | $46.4M | −$122.4M | −$31.8M | $49.0M |
| EBITDA | $158.7M | $124.2M | $157.4M | $130.2M | $143.3M | −$34.6M | $51.5M | $284.2M |
| Net income | $41.8M | $117.0M | $99.9M | $10.0M | −$5.8M | −$189.3M | −$44.8M | $146.7M |
| Net margin | 8.9% | 25.1% | 20.0% | 2.0% | -1.1% | -107.1% | -15.2% | 36.1% |
| EPS (diluted) | 0.56 | 2.21 | 1.79 | 0.25 | -0.15 | -4.90 | -1.15 | 4.03 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds HT.
No tracked institution reports a position in HT as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2023-09-28 | $0.0500 | 2023-10-16 |
| Execution date | Ratio |
|---|---|
| 2015-06-23 | 1-for-4reverse |
No one on the platform has traded HT yet.
| +0.00% |
| $412M |
| — |
| NHPAPNational Healthcare Properties, Inc. | $23.15 | +0.74% | $655M | — |
| NYMTNew York Mortgage Trust, Inc. | $7.11 | -1.52% | $642M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
@calemay brother in law retired quantum physics professor. Never understood any of that $HT. But I guess it's going to arrive soon or maybe already?
View on StockTwits ↗$MSTR Let’s Recap: Heading into November 2024 - Holy $ht! Look at MSTR fly! Saylor ramps up heavily diluting and creating exotic preferreds that ”pay” a dividend…by issuing more commons January 2025 - “When DJT enters office and creates the Strategic Bitcoin Reserve” MSTR will fly! Then that didn’t pan out. April 2025 - “When the tariff drama ends BTC will hit 200k and MSTR will fly!“ Then that didn’t happen June 2025 - “When MSTR blows out earnings due to GAAP accounting rule changes…MSTR will fly!” Then that didn’t happen August 2025 - ”When MSTR is included in S&P 500 it will fly!” - Most likely not happening All the while Saylor keep diluting commons, depressing volatility, increasing credit risk, and pumping propaganda….and stock is down 40+% Guy is getting roasted on X right now and it’s well deserved. As a long time MSTR trader…I am out.
View on StockTwits ↗$BBAI dang. Just got back to desk. BigBear must have taken $ht in woods.
View on StockTwits ↗$BINI David thinks his crapcoin will continue also. You cannot make this $Ht up. A 12 year old could have planned this out since 2015 but here we are! Just unbelievable.
View on StockTwits ↗$ILLR he said, she said, they said, these keyboard warriors don't know $ht. Get your headsets back on and go back to playing video games. Who actually believes someone would work for a company 3 months without a paycheck.
View on StockTwits ↗@asweidan Glad we’re on the same side, Ala, cuz I sure as $ht don’t want to bet against you!
View on StockTwits ↗@Unionmantn 1) It’s standard protocol to include RS option in a proxy vote for a biopharma at this stage. The document was probably created during a Board meeting in February when share price was low. It hasn’t been voted on to allow it in 2025. There’s only a 1:2 RS allowed from 2024 authorization left. We don’t need it. 2) A RS isn’t needed when the stock price is trading at optimal price for liquidity, between $20 -$200. The price will stay above $10 and work back up. (I’m not saying it will go down to $10) 3) A RS doesn’t cause dilution. It just exchanges two $5 bills for a $10 bill. Reducing shares reduces liquidity though. But RS is not dilution. It’s just a technical trick associated with penny stocks and has that stigma. 4) At the money stock issues (ATM) cause actual dilution, which is bothersome but worth riding out for 20x gains. 5) RS not needed unless crazy $ht really hits the fan. It won’t. Next earnings report will be stuffed with cash.
View on StockTwits ↗@Elbasan 1) It’s standard protocol to include RS option in a proxy vote for a biopharma at this stage. The document was probably created during a Board meeting in February when share price was low. It hasn’t been voted on to allow it. There’s only a 1:2 RS allowed from 2024 authorization left. 2) A RS isn’t needed when the stock price is trading at optimal price for liquidity, between $20 -$200. The price will stay above $10 and work back up. (I’m not saying it will go down to $10) 3) A RS doesn’t cause dilution. It just exchanges two $5 bills for a $10 bill. Reducing shares reduces liquidity though. But RS is not dilution. It’s just a trick associated with penny stocks and has that stigma. 4) At the money stock issues (ATM) cause actual dilution, which is bothersome. 5) RS not needed unless crazy $ht really hits the fan. It won’t. Next earnings report will be stuffed with cash.
View on StockTwits ↗@StonedHedge1 Serv is making me hungry. Gotta find good entries on these movers. Late in the game to these two digit percentage moves is precarious. A lot of $ht is melting up.
View on StockTwits ↗buy the dips my a$$. I've done that for 3 months only to have my shares cut in half and my average go to $ht. I'm not selling but I damn sure am not buying more.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.